Hologic, Inc. (NASDAQ:HOLX) Shares Bought by TD Asset Management Inc

TD Asset Management Inc grew its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,935,189 shares of the medical equipment provider’s stock after purchasing an additional 348 shares during the period. TD Asset Management Inc’s holdings in Hologic were worth $143,688,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of HOLX. International Assets Investment Management LLC acquired a new stake in shares of Hologic in the fourth quarter worth approximately $950,000. Kestra Private Wealth Services LLC acquired a new stake in shares of Hologic in the fourth quarter worth approximately $224,000. Lincoln National Corp boosted its position in shares of Hologic by 4.0% in the fourth quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock worth $334,000 after acquiring an additional 178 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Hologic by 1.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,446,768 shares of the medical equipment provider’s stock worth $103,372,000 after acquiring an additional 26,730 shares during the last quarter. Finally, Principal Securities Inc. acquired a new stake in shares of Hologic in the fourth quarter worth approximately $115,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Trading Down 0.8 %

HOLX opened at $80.99 on Friday. The firm has a market capitalization of $18.90 billion, a P/E ratio of 41.32, a P/E/G ratio of 2.57 and a beta of 0.99. The firm’s 50 day moving average is $79.30 and its 200-day moving average is $76.57. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.93 earnings per share. Analysts expect that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several research analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Evercore ISI raised their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 30th. Stephens reaffirmed an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. JPMorgan Chase & Co. lifted their price target on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Finally, Argus lifted their price target on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Insider Activity

In other news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now owns 45,472 shares in the company, valued at $3,615,024. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares in the company, valued at $3,615,024. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock worth $1,469,973 over the last 90 days. Company insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.